MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose MM-120 100µg demonstrated a clinically and statistically significant HAM-A...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials